

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 8-K

DUSA PHARMACEUTICALS INC
Form 8-K
January 15, 2004

FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 15, 2004

DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

NEW JERSEY (State or other jurisdiction of incorporation)	0-19777 (Commission File Number)	22-3103129 (IRS Employer Identification Number)
--------------------------------------------------------------------	--------------------------------------------	--------------------------------------------------------------

25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887

(Address of principal executive offices, including ZIP code)

(978) 657-7500
(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS.

DUSA Pharmaceuticals, Inc. ("DUSA") issued a press release on January 15, 2004, attached to and made part of this report, reporting preliminary Q4 2003 end-user Levulan(R) Kerastick(R) net sales to physicians from its distributors and the promotion of Peter Chakoutis, DUSA's Controller, to Vice President and Chief Financial Officer and the promotion of Richard Christopher to the new position of Vice President, Financial Planning and Business Analysis, both effective January 1, 2004.

ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS.

(c) Exhibits.

[99] Press Release dated January 15, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 8-K

undersigned hereunto duly authorized.

DUSA PHARMACEUTICALS, INC.

Dated: January 15, 2004

By: D. Geoffrey Shulman

D. Geoffrey Shulman, MD, FRCPC
President, Chief Executive Officer